The prevalence and severity of duodenal injury in coeliac disease patients controlled on a gluten-free diet is unclear.
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INTRODUCTION
Persistent duodenal mucosal damage in patients with coeliac disease on gluten-free diet is associated with increased severe long-term complications (1) . A recent meta-analysis found 31% of patients with coeliac disease had persistent villus atrophy on gluten-free diet, and only half of these patients had elevated transglutaminase 2 (TG2) IgA serology (2) . A corollary of these findings is that about one in five patients apparently well controlled on gluten-free diet with normal TG2 serology has duodenal villus atrophy. These conclusions are, however, based on routine processing, and subjective or semiquantitative analysis of biopsies, usually from the distal duodenum.
Quantitative histology provides accurate assessment of duodenal mucosal injury in coeliac disease by using highly reproducible measurements of villous height, crypt depth and intra-epithelial density in well-oriented distal duodenal biopsies (3, 4) . With implementation of rigorous standard operating procedures, quantitative duodenal histology outperforms conventional qualitative histology using grouped classifications such as Marsh score (5) (6) (7) , and is emerging as a preferred measure of efficacy in therapeutics trials for coeliac disease (5, (8) (9) (10) . Perhaps surprisingly, quantitative histology has not yet, to our knowledge, been used to evaluate disease activity/duodenal injury in patients who appear "well-controlled" coeliac disease and are in serological remission.
Quantitative histology in baseline duodenal biopsies collected in phase 1 and 2 clinical trials assessing an investigational immunotherapy, Nexvax2®, for coeliac disease provided the opportunity to assess duodenal injury in patients with "well-controlled" coeliac disease on gluten-free diet (11) (12) (13) . The primary objective of this study was to use quantitative histology to assess duodenal mucosal injury in treated coeliac disease, and in particular those patients who are well established on gluten-free diet, and in serological remission.
METHODS
Study design
The study analysed quantitative histology of duodenal biopsies collected during the pre-treatment This article is protected by copyright. All rights reserved were recruited at sites in Australia, New Zealand, and the United States. In each study, a subgroup of patients had biopsies collected as a safety assessment before and after the treatment period. Details of the four studies are summarized in Table 1 . In the three phase 1 studies, which have been reported in detail elsewhere (11, 12) , patients with coeliac disease were maintaining their usual gluten-free diet had no study interventions before their pre-treatment biopsy. In the phase 2 ("RESET CeD") trial, which has also been described elsewhere (13) , patients with coeliac disease were maintaining their usual gluten-free diet, but had a single bolus gluten challenge (6 grams of gluten protein taken as 10 grams vital wheat gluten flour in water) three weeks before biopsy collection according to the protocol described by Tye-Din et al (14).
Patients and interventions
All patients gave written, informed consent prior to undergoing any trial-related procedures.
Eligibility criteria for each clinical trial have been reported fully elsewhere (11) (12) (13) . In brief, for all four studies, patients who had biopsies collected had met initial screening criteria, which included being aged between 18 to 70 years, having documented duodenal villus atrophy while consuming gluten, being positive for HLA-DQA1*05 and DQB1*02 ("HLA DQ2.5"), and having maintained a gluten-free diet for at least one year. Patients with uncontrolled complications of celiac disease including refractory coeliac disease were excluded. In phase 1 studies, additional study-specific eligibility criteria were intended to select for patients entering the treatment period who were strictly maintaining a gluten-free diet. In the first and second phase 1 studies, patients who had a known gluten exposure within two months prior to screening were excluded, and patients were discontinued if subjective assessment of Marsh class for any pretreatment biopsy was more severe than 1 (raised intra-epithelial lymphocytes with normal villous architecture). In the third phase 1 study, patients were excluded if both TG2 IgA and deamidated gliadin peptide IgG serology were elevated, or if their score in the Celiac Dietary Adherence Test suggested non-compliance to gluten-free diet. In the phase 2 study, patients in the biopsy subgroup had met the inclusion criteria that experienced worsening digestive symptoms on the day of screening gluten food challenge three weeks earlier. 
Quantitative duodenal histology
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This article is protected by copyright. All rights reserved Biopsy collection, processing and quantitative histology methods in the first and second phase 1 studies have been described in detail elsewhere (3, 11, 12) . Briefly, biopsies were collected from four sites: the duodenal bulb, and from the first, second, and third parts of the duodenum. Two biopsies were obtained at each site with a single biopsy per pass of the forceps, and placed in formalin fixative.
Both biopsies from each site were processed together; they were embedded in paraffin, sectioned, and stained with haemotoxylin and eosin, and by anti-CD3 immunochemistry. The pathologist at the central laboratory made a subjective assessment of whether a patient had any biopsy consistent with a and villus height to crypt depth ratio 0.0-0.4 for M3c (15) .
In the third phase 1 study and phase 2 study, biopsy collection was limited to the second part of the duodenum, PAXgene tissue fixative (QIAGEN, Hilden, Germany) was used, and biopsies were sent directly to Jilab Inc. (Tampere, Finland) for processing and quantitative histology. Biopsy collection and handling, and the protocol for quantitative histology are described elsewhere (3, 12, 16) . Paxgene fixative facilitated a wider repertoire of immunohistochemical, immunofluorescence assessments, and genome-wide transcriptome analysis in the same tissue sample (16) . In brief, after collection, biopsies PAXgene dual-chamber fixative containers (Qiagen #765112, Venlo, Netherlands). Samples in fixative were shipped at ambient temperature and then stored at +4°C until processing. Each biopsy was embedded in a separate paraffin block under a dissection microscope and aimed for a cutting plane perpendicular to the mucosal lumen surface to orientate the specimens correctly. As for the earlier studies, the slides were stained with haematoxylin and eosin and by anti-CD3 immunochemistry. De-identified slides were scanned as whole-slide images using a SlideStrider scanner at a resolution of 0.28 μm per pixel (Jilab Inc., Tampere, Finland). Images were stored as JPEG2000 files in the image server and viewed over the Internet with web-based client software 
Statistical analyses
No formal power calculation was undertaken for these exploratory, post hoc analyses. Non-parametric tests were used to assess the significance of differences in paired (Wilcoxon signed rank test) or unpaired (Mann-Whitney test) observations, and to assess correlations (Spearman's coefficient). All statistical tests were 2-tailed. Summary and significance statistics were computed using Graphpad Prism V7.0d. Table 1 shows the characteristics of the 93 patients who had pre-treatment duodenal biopsies collected across three phase 1 trials and one phase 2 study investigating Nexvax2 in patients with coeliac disease. Disposition of patients in the phase 1 studies who had biopsies has been reported previously, This article is protected by copyright. All rights reserved (11, 12) and is shown in Figure S1 for patients in the phase 2 study. Patient characteristics were similar for the four studies. The median period since diagnosis of coeliac disease was six years. Three (4%) of the 85 patients who had serology evaluated had elevated levels of transglutaminase IgA. At screening, 30 (75%) patients in phase 1 studies and 48 (91%) patients in the phase 2 study had been diagnosed and managed with a gluten-free diet for at least two years, and were confirmed seronegative for TG2-specific IgA.
RESULTS
Patient characteristics
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Quantitative histology in second part duodenal biopsies
Overall, among all 93 patients assessed, Table 2 shows six (6%) had second part duodenal biopsies classified as Marsh class 0 or 1, 30 (33%) had Marsh 2, and 56 (60%) had Marsh 3a or 3b. The proportion of patients with second part duodenal histology graded as Marsh 3 was similar for each study. There were non-significant trends for Marsh 3a and 3b classification to be less prevalent in patients confirmed as seronegative for transglutaminase 2 IgA who had been diagnosed for at least two years (58%) compared to other patients (78%), and more prevalent in patients subjectively assessed during screening in phase 1 studies as having Marsh class worse than 1 (84%) than those subjectively assessed as Marsh 0 or 1 (68%). Table 3 shows that there was no difference in the distribution of Marsh grades between patients recruited in Australia, New Zealand, and the United States.
Proximal to distal changes in duodenal quantitative histology
For all 26 patients having pre-treatment biopsies in the first and second phase 1 Nexvax2 clinical trials, two biopsies were collected from each of the bulb, first, second and third part of the duodenum. This article is protected by copyright. All rights reserved 0.66, P = 0.0003) and third part (r s = 0.76, P < 0.0001) in the same patient. Villous height to crypt depth ratio in second part biopsies was significantly correlated with the first part (r s = 0.35, P = 0.044) and third part (r s = 0.41, P = 0.021) in the same patient.
Quantitative histology identifies mucosal injury overlooked by subjective assessment
It is well known that most small bowel mucosal biopsies are currently processed without orientation in the endoscopy or pathology laboratory, and that poor orientation may compromise interpretation of villus-crypt architecture (17). In PAXgene fixed biopsies in the present study, Marsh class changed with level of cutting in the same biopsy block, as presented in Figure 2 . For example, the section shown in Figure 2A was classified as Marsh 1 (tall villi and increased intra-epithelial lymphocytes) becomes a crypt hyperplastic lesion classified as Marsh 3a in Figure 2F , and Figure 2C shows to the right, where the cutting is perpendicular to the luminal surface, a crypt hyperplastic lesion classified as Marsh 3c. When measuring all readable villus-crypt units in the six histology sections presented, the global mean villus height to crypt depth ratio is 0.85, i.e. Marsh class 3b according to Taavela et al (16) . Hence, to improve orientation of tissue sections prepared by the central laboratory and allow accurate assessment by quantitative histology, 40% of biopsies from the first and second phase 1 studies were re-cut. Overall, 26 (100%) patients had biopsies from at least one location graded as Marsh class 3a, 3b, or 3c (median 3b) by quantitative histology, which contrasted with the subjective assessment during screening that 20 (77%) had duodenal histology no worse than Marsh 1.
Villus height is linked to variability in duodenal villus-crypt length
The height of the villus-crypt axis (i.e. the sum of villus height and crypt depth) has been depicted as a constant, which implies that there is a reciprocal relationship between villus height and crypt depth (4) . Figure 3 shows the relationships between measurements of duodenal villus height and crypt depth, and their ratio or sum for the pooled set of 169 biopsy assessments from 93 patients. As expected, villus height and crypt depth are significantly, but rather weakly correlated ( Figure 3A and negatively with crypt depth (r s = 0.74, P <10 -10 ) ( Figure 3C ). However, villus height increases about four-times more rapidly than crypt depth decreases as the sum of villus height and crypt depth increases ( Figure 3D) , and the sum of villus height and crypt depth is correlated strongly positively with villus height (r s = 0.82, P <10 -10 ) and weakly negatively, but significantly, with crypt depth (r s = -0.22, P = 0.004). When analysed separately, the correlation between the sum of villus height and crypt depth and villus height was statistically significant for each study and for each region of the duodenum (Table S1 ). Collectively, these findings provide support for a model of mucosal behavior, healing and deterioration that involves not just reciprocal changes in villus height and crypt depth, but also includes increasing villus-crypt length as villus height increases in patients with coeliac disease on gluten-free diet (Figure 4 ).
DISCUSSION
This study used quantitative histology to assess duodenal mucosal injury in 93 patients with treated coeliac disease who enrolled in clinical trials of an investigational immunotherapy. Eligibility criteria for these clinical trials were intended to select for patients who were well-controlled on gluten-free diet, and consequently, transglutaminase IgA serology was elevated in fewer than 5% of participants tested. Altogether, quantitative histology of biopsies from the second part of the duodenum indicated mucosal "healing" (Marsh 0) in only one case, mucosal recovery (Marsh 0 -2) in 36 (38%), and persistent villus atrophy (Marsh 3a, 3b or 3c) in 57 (61%) cases. Mucosal recovery (42%) and persistent villus atrophy (58%) were similar for the subgroup of 78 (84%) patients we defined as "well-controlled", who were sero-negative for transglutaminase antibodies and had been established on gluten-free diet for at least two years. Severity of mucosal injury was similar across the three countries where patients were recruited, Australia, New Zealand and the United States. Persistent villus atrophy revealed by quantitative histology in our cohort of "well-controlled" patients is, in fact, higher than the 38% recently reported for 1,345 patients with self-reported moderate or severe coeliac disease-associated symptoms (4) . Even though it is well-known that persistent duodenal villus atrophy is not efficiently detected by transglutaminase serology in patients on gluten-free diet (2), our findings suggest that standard processing and subjective evaluation of duodenal biopsies also fails to detect no crypts cut longitudinally appeared to contribute to unrecognized mucosal injury in our study, and has been highlighted in recent pathology guidelines (17). A novel aspect of our study was to assess quantitative histology at four duodenal sites from the bulb to third part. Villus flattening was significantly more severe in the proximal duodenum, but intraepithelial lymphocyte density was modestly higher in the distal duodenum. An unexpected finding was that the combined length of the duodenal villus-crypt unit can vary by as much as 50%, and this can be attributed to relative increases in villus height being four times as much as decreases crypt depth. These findings provide support for a model of mucosal behavior, healing and deterioration that involves not just reciprocal changes in villus height and crypt depth, but also includes increasing villus-crypt length as villus height increases in patients with coeliac disease on gluten-free diet (Figure 4 ).
Our study had several limitations. Biopsies evaluated were from patients in subgroups of those enrolled in four clinical trials testing an experimental immunotherapy. These patients may not be representative of randomly selected patients in Australia, New Zealand, or the United States because the eligibility criteria were intended to ensure only patients well-controlled on gluten-free diet were enrolled. Notably, the prevalence of elevated transglutaminase IgA serology in our study patients was similar to that reported in recent follow-up studies from Norway, Finland and Australia that reported persistent villus atrophy in 4% to 15% of adults on gluten-free diet for more than five years (18-20).
Although the patients in phase 1 studies had no per protocol gluten exposure before collection of biopsies, those in the phase 2 study had consumed a bolus of six grams of gluten three weeks before biopsy collection. Consequently, biopsies in the phase 2 study may have shown residual effects of this gluten exposure, even though Marsh classes in these patients were similar to milder than those from phase 1 study patients. Although an important practical consideration for future studies, this study did concerning for patients and treating physicians, but in this study was rectified by re-cutting biopsies with poorly orientated tissue sections. A further limitation of our findings might be that we did not consider potential drug-induced enteropathy to occur in our study subjects, for example subjects using Olmesartan (21), proton pump inhibitors, non-steroidal anti-inflammatory drugs or selective serotonin reuptake inhibitors (22).
This study had four principal findings. We confirm that quantitative histology demonstrates persistent duodenal mucosal injury in the majority of patients with coeliac disease on gluten-free diet (4), and extend this observation to patients who are sero-negative and would be considered "well-controlled".
Second, villus height to crypt depth ratio, and intra-epithelial lymphocytosis increase progressively from the proximal to distal duodenum. This finding highlights the importance of standardizing anatomical sites where biopsies are collected during clinical follow-up and in clinical trials. Third, there is a strong positive correlation between villus height and overall crypt-villus length, which may provide additional information regarding healing of the mucosa. Finally, there is a marked discrepancy between subjective histology and quantitative histology when evaluating duodenal mucosal injury in patients on gluten-free diet. While quantitative histology is unlikely to be practical in routine laboratory assessment of duodenal biopsies, our findings suggest that the clinical value of follow-up histology could be improved by adhering to published guidelines (17), which could more accurately reveal previously unrecognised mucosal injury in patients with coeliac disease on glutenfree diet. 
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